Generali Investments CEE investicni spolecnost a.s. Buys Shares of 2,000 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Generali Investments CEE investicni spolecnost a.s. bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,000 shares of the biotechnology company’s stock, valued at approximately $243,000.

Several other large investors have also recently bought and sold shares of the company. CIBC Asset Management Inc increased its stake in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 86 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after buying an additional 100 shares during the period. Manchester Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the period. UMB Bank n.a. increased its stake in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 145 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. HC Wainwright reaffirmed a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Finally, StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $170.41.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 2.4 %

SRPT stock opened at $103.03 on Monday. Sarepta Therapeutics, Inc. has a twelve month low of $99.50 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock’s 50 day moving average is $114.11 and its 200-day moving average is $121.27. The firm has a market capitalization of $10.00 billion, a PE ratio of 82.42 and a beta of 0.79.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.